Skip to main content
OpenTrials
Completed

NCT Number: NCT04212260

Oropharyngeal Exercises and Post-Stroke Obstructive Sleep Apnea

This study evaluates the feasibility and effectiveness of an oropharyngeal exercise (O-PE) regimen in treating post-stroke obstructive sleep apnea, as an alternative therapy to continuous positive airway pressure (CPAP). Eligible patients will be randomized (1:1) to treatment using a pre-specified schedule of O-PEs vs. a sham control arm.

Completed

Looking for future studies?

Notify Me

Key information

About this study

BACKGROUND Obstructive sleep apnea (OSA) is characterized by recurrent obstruction of the upper airway during sleep due to intermittent loss of pharyngeal dilator muscle tone. OSA is both a risk factor for stroke, as well as a common post-stroke co-morbidity with approximately 72% of patients with stroke or transient ischemic attack (TIA) having OSA. Post-stroke OSA is linked to post-stroke, fatigue, which is a top research priority for stroke patients. Moreover, post-stroke OSA is associated with greater mortality, a higher risk of recurrent stroke, poorer cognition and lower functional status. In addition, stroke patients with OSA spend significantly longer times in rehabilitation and in acute care hospitals. Since OSA has a significant impact on the health of stroke patients, it is imperative that effective treatments are used to assist patients. Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with moderate to severe OSA. However, despite having been demonstrated to improve post-stroke cognition, motor and functional outcomes,and overall quality of life, rates of CPAP adherence are low. Reasons for poor post-stroke CPAP adherence are multi-factorial and often not easily modifiable. Overall, there is a major clinical need to develop an alternative effective and well-tolerated treatment for OSA.

Oro-pharyngeal exercises (O-PEs) are commonly used by speech-language pathologists to improve oro-motor strength and range of motion and serve as a promising alternative approach to treat OSA. For example, in a randomized controlled trial in which patients with moderate OSA underwent 3 months of daily exercises focusing on strengthening oro-pharyngeal musculature, OSA severity and symptoms were demonstrated to be significantly reduced compared to sham exercises.Similarly, use of the didgeridoo, a wind instrument that strengthens muscles of the upper airway, has also been demonstrated to reduce OSA severity.

METHODS Research Question: Is a randomized controlled trial (RCT) of an O-PE regimen in post-stroke OSA feasible?

Primary Objective: To examine whether an RCT of an O-PE regimen is feasible in stroke patients with OSA who are unable to tolerate CPAP. (i) The O-PE regimen will be considered feasible if >80% of enrolled patients complete >80% of the study exercises. (ii) We will also track the monthly number of eligible vs. recruited patients from Dr. Boulos' stroke and sleep disorders clinic. Hypothesis: An RCT of an O-PE regimen in post-stroke OSA will be feasible in that >80% of enrolled patients will complete >80% of the study exercises.

Secondary Objectives: To explore whether an O-PE regimen, compared to sham activities, might be effective in (i) improving various objective sleep metrics (i.e. OSA severity and nocturnal oxygen saturation), (ii) improving various measures of oropharyngeal physiology and function (i.e. oro-pharyngeal deficits and dysarthria, tongue/lip/jaw weakness, and oro-facial kinematics), and (iii) enhancing self-reported sleep-related symptoms. Hypothesis: Compared to the sham activities, O-PEs will positively influence the outcomes noted above.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Imaging-confirmed stroke or stroke specialist-diagnosed transient ischemic attack (TIA)
  • Prior diagnosis of OSA by a physician at any time in the past.
  • Unable to tolerate CPAP after a 2-week trial of CPAP

Exclusion criteria

  • BMI > 40 kg/m2
  • The presence of conditions known to compromise the accuracy of portable sleep monitoring, such as moderate to severe pulmonary disease or congestive heart failure.
  • Oxygen therapy (e.g. nasal prongs), a nasogastric tube, or other medical device that would interfere with the placement of the home sleep apnea test
  • Cranial malformations/nasal obstruction
  • Significant depressive symptoms
  • Regular use of hypnotic medications
  • Other neuromuscular diseases or conditions affecting oropharyngeal muscles
  • Montreal Cognitive Assessment (MoCA) < 18
  • Aphasia
  • Oral or apraxia of speech

Treatment and study plan

oropharyngeal exercises

Behavioral

Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.

Sham Control

Behavioral

Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.

Primary outcomes

  1. Percentage of enrolled participants completing >80% of the study exercises

    Time frame: 6-10 weeks (post-training)

    The study exercise regimen will be deemed feasible if >80% of enrolled patients complete >80% of the study exercises. Patient adherence with study exercises in both treatment arms will be recorded (in minutes) via use of the App that will deliver the oropharyngeal exercises/sham exercises. Completion of >80% of the study exercises would be indicated by >720 recorded minutes (if post-training visit is after 6 weeks) or >1200 recorded minutes (if post-training visit is after 10 weeks).

Secondary outcomes

  1. OSA severity (as measured by the apnea-hypopnea index)

    Time frame: Baseline, 6-10 weeks (post-training), and 10-14 weeks (retention)

    Measured by the apnea-hypopnea index (AHI). AHI quantifies the number of apneas and hypopneas per hour of sleep. It will be measured using a home sleep monitor that has been validated for use in the stroke population.

  2. Lowest oxygen desaturation

    Time frame: Baseline, 6-10 weeks (post-training), and 10-14 weeks (retention)

    Lowest oxygen desaturation will be measured using a home sleep monitor that has been validated for use in the stroke population.

  3. Oro-pharyngeal deficits and dysarthria (as measured by the second version of Frenchay Dysarthria Assessment)

    Time frame: Baseline, 6-10 weeks (post-training), and 10-14 weeks (retention)

    The second version of Frenchay Dysarthria Assessment (FDA-2) is divided into 7 sections: reflexes, respiration, lips, palate, laryngeal, tongue, and intelligibility, each containing several individual items. Each item is rated on a scale from "0" to "7", where "0" means normal for age, and "7" means unable to undertake task/movement/sound. The total score of the 7 sections will determine the severity of dysarthria.

  4. Tongue/lip/jaw weakness

    Time frame: Baseline, 6-10 weeks (post-training), and 10-14 weeks (retention)

    Measured by the Iowa Oral Performance Instrument & Flexiforce (max pressure, endurance)

  5. Oro-facial kinematic capacity

    Time frame: Baseline, 6-10 weeks (post-training), and 10-14 weeks (retention)

    Oro-facial kinematic capacity is defined by the range of facial motions (in mm) for lips and jaw, assessed during a standardized series of oro-motor tasks (e.g. Maximum mouth opening, syllable repetition)

  6. Functional status (as measured by Functional Outcomes of Sleep Questionnaire)

    Time frame: Baseline, 6-10 weeks (post-training), and 10-14 weeks (retention)

    Functional Outcomes of Sleep Questionnaire (FOSQ) encompasses 5 subscales: activity level, vigilance, intimacy and sexual relationships, general productivity, social outcome. An average score is calculated for each subscale and the 5 subscales are totaled to produce a total score. Subscale scores range from 1-4 with total scores ranging from 5-20. Higher scores indicate better functional status.

  7. Daytime sleepiness (as measured by Epworth Sleepiness Scale)

    Time frame: Baseline, 6-10 weeks (post-training), and 10-14 weeks (retention)

    Scores on Epworth Sleepiness Scale range from range from 0 to 24, with higher scores indicating higher average sleep propensity in daily life (daytime sleepiness).

  8. Fatigue (as measured by Fatigue Severity Scale)

    Time frame: Baseline, 6-10 weeks (post-training), and 10-14 weeks (retention)

    Fatigue Severity Scale measures the severity of fatigue and its effect on a person's activities and lifestyle. Scores range from 9 to 63, with higher scores indicating greater fatigue severity.

  9. Quality of Life (as measured by Stroke Impact Scale)

    Time frame: Baseline, 6-10 weeks (post-training), and 10-14 weeks (retention)

    Stroke Impact Scale (SIS) assesses multidimensional stroke outcomes through 8 domains: strength (raw score range: 4-20), hand function (5-25), activities of daily living (score range 10-50), mobility (score range 9-45), communication (score range 7-35), emotion (score range 9-45), memory and thinking (score range: 7-35), and participation (8-40). Each domain is scored separately. For each domain, raw scores are transformed using the following formula: Transformed Scale = (Actual raw score - lowest possible raw score)*100 / (Possible raw score range). Higher scores indicate greater quality of life.

  10. Cognitive ability (as measured by Montreal Cognitive Assessment)

    Time frame: Baseline, 6-10 weeks (post-training), and 10-14 weeks (retention)

    Montreal Cognitive Assessment (MoCA) is a screening test for detecting cognitive impairment. Scores range from 0 to 30, with higher scores indicating greater cognitive ability.

Sponsors and collaborators

Lead sponsor

Sunnybrook Health Sciences Centre

Other

Collaborators

  • Sunnybrook Research Institute
  • Toronto Rehabilitation Institute
  • Unity Health Toronto
  • University of Toronto

Registry information

Official study title

Strengthening Oropharyngeal Muscles as a Novel Approach to Treat Obstructive Sleep Apnea After Stroke: A Randomized Feasibility Study

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Dec 26, 2019
Registry last updated
Apr 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.